Renflexis
Renflexis
Renflexis (infliximab-abda) is a biosimilar of Remicade. Renflexis is indicated for the treatment of Crohn’s Disease, pediatric Crohn’s Disease, Ulcerative Colitis, Rheumatoid Arthritis, Ankylosing Spondylitis, Psoriatic Arthritis and Plaque Psoriasis. Inflectra is administered as an intravenous infusion.
Administration Information
A biosimilar is a medicine approved by the Food and Drug Administration (FDA) as being highly similar to an already approved biologic medicine. The FDA refers to the already approved biologic as the reference product. It is also known as the originator or original biologic product.
Gram of IV Iron
0
days apart
0
days apart
0
-8
Potential Side Effects
RENFLEXIS treats the same autoimmune diseases as Remicade. It works the same way, has the same dosage and is taken the same way. This means you can expect similar safety and effectiveness from the biosimilar over the course of treatment as you would from the reference product.
Patient Forms
Before you attend your first appointment at Omega Health, please make sure to review the documents below. The Patient Consent Form and HIPAA Privacy Authorization Form need to be filled out and signed ahead of your appointment, whereas the Notice of Privacy Practices and Patient Rights and Responsibilities are for reference only. Please contact us if you have any questions!
Patient Consent Form
Print & Sign
HIPAA Privacy Authorization Form
Print & Sign
Notice of Privacy Practice
Read
Patient Rights and Responsibilities
Read
Appointment Lateness and Cancelation
Read
